Navigation Links
Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics
Date:6/4/2011

SHENZHEN, China, June 4, 2011 /PRNewswire/ -- To aid the fight of the deadly outbreak of E. coli O104 strain in Europe, BGI-Shenzhen and their collaborators at the University Medical Centre Hamburg-Eppendorf have released an updated draft genome assembly result built upon the sequencing data previously released and submitted to NCBI in the previous two days. As one of the first genomes assembled using the latest ion semiconductor sequencing technology, there were some initial difficulties assembling the genome, but a de novo assembly approach was applied first, and gene structures were refined with the assistance of genomic sequences from related strains.

This newly assembled draft genome is a large improvement on the previous version and is now freely accessible from the NCBI database (http://www.ncbi.nlm.nih.gov/bioproject/67657) and BGI website (ftp://ftp.genomics.org.cn/pub/Ecoli_TY-2482). The rapid release and dissemination of this data to the scientific community by the BGI, aided for the first time by new media forms such as Twitter (follow: @BGI_Events), has in less than 24-hours allowed researchers around the world to produce alternative genome assemblies, and now allows comparisons with additional, and potentially different isolates and strains (see: http://pathogenomics.bham.ac.uk/blog/2011/06/ehec-genome-assembly/).   This data should also aid in the development of diagnostic tests, as well as help to resolve issues regarding the outbreak's origin.

While preliminary, considerable additional information has been derived from this latest dataset in addition to that announced previously (see: http://www.genomics.cn/en/news_show.php?type=show&id=644). Based on the draft assembly, the genome of this outbreak strain is a mosaic containing genes from a variety of strains. This data further confirms the serotype of the outbreak strain is O104, and while O104 E. coli strains have previously been implicated in outbreaks in the United States, BGI's initial results suggest that the current outbreak and the previous US O104 strain are genetically distinct. The sequences of seven housekeeping genes from the outbreak strain were also used in MLST (multi-locus sequences typing) analysis against 3,800 E. coli strains (http://mlst.ucc.ie/), and all seven genes were found to be different between the US and current outbreak strain.

BGI researchers also investigated whether previously reported E. coli virulence genes were present in the outbreak strains, and from its initial analysis only stx2 has been identified so far, and no previously described virulence gene has been detected in the outbreak strain. In contrast to this, a further five antibiotic-resistant genes have been identified on top of the three identified in the initial assembly, including cephalosporin, monobactam, penicillin and streptomycin, which provides further genetic evidence that the strain is at resistant to at least eight different types of antibiotics.

While the data released so far is only preliminary and should be used with that in mind, due to its great importance to public health the research group is making it immediately available to the community for download without restriction. The group will continue to improve the assembly with additional upcoming data, and will continue to release updated versions to facilitate the campaign against this deadly bacteria.

About BGI

BGI (formerly known as Beijing Genomics Institute) was founded in 1999 and has become the largest genomic organization in the world. With a focus on research and applications in the healthcare, agriculture, conservation and bio-energy fields, BGI has a proven track record of innovative, high-profile research which has generated over 178 publications in top-tier journals such as Nature and Science. BGI's distinguished achievements have made a great contribution to the development of genomics in both China and the world. Our goal is to make leading-edge genomics highly accessible to the global research community by leveraging industry's best technology, economies of scale and expert bioinformatics resources. BGI and its affiliates, BGI Americas and BGI Europe, have established partnerships and collaborations with leading academic and government research institutions, as well as global biotechnology and pharmaceutical companies. At BGI, we have built the infrastructure and scientific expertise to enable our customers and collaborators to quickly migrate from samples to discovery. For more information, visit www.bgiamericas.com or www.bgisequence.com.


'/>"/>
SOURCE BGI
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Rainbow-trapping scientist now strives to slow light waves even further
2. Precision Therapeutics Announces New Tumor Profiling Product to Augment Utility of ChemoFx® and Further Personalize Cancer Treatment
3. Sigma® Life Science Joins AMDeCs Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers
4. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
5. Winners of inaugural defense fellowships to further research at NTU
6. U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
7. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
8. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
9. Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
10. Chemopreventative Effects of Protandim® Examined Further in New Peer-Reviewed Study
11. China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Wisconsin (PRWEB) , ... February 23, 2017 , ... ... Drug Discovery Services portfolio to include an array of biochemical analyses ... with reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency ...
(Date:2/23/2017)... Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, with its ... place for a head lice treatment salon to set up ... Tuscan restaurant and a French bistro on E Madison Ave, ... aren,t just any old lice clinic, we pride ourselves on ... and release some of the stigma associated with lice. Everyone ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, PhD accepted Purdue ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization ... to, and success with, commercializing discoveries from Purdue research. “This award is truly ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
Breaking Biology Technology:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
Breaking Biology News(10 mins):